Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB -0.43%70 EV-to-OCF is -60.88 as of Aug. 11, 2026. GuruFocus rates CTKB with a GF Score™ of 70/100 and a GF Value™ of $5.58 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 94.37% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cytek Biosciences's Enterprise Value is $367.6 Mil.
Cytek Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-6.0 Mil. Therefore, Cytek Biosciences's EV-to-OCF for today is -60.88.
The historical rank and industry rank for Cytek Biosciences's EV-to-OCF or its related term are showing as below:
CTKB'
s EV-to-OCF Range Over the Past 10 Years
Min: -762.59 Med: 12.56 Max: 938.49
Current: -60.88
During the past 7 years, the highest EV-to-OCF of Cytek Biosciences was 938.49. The lowest was -762.59. And the median was 12.56.
CTKB's EV-to-OCF is ranked better than 94.37% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.85
vs CTKB: -60.88
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cytek Biosciences's PE Ratio (TTM) for today is calculated as:
Cytek Biosciences's share price for today is $4.64.
Cytek Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cytek Biosciences EV-to-OCF Related Terms
Cytek Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cytek Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's EV-to-OCF falls into.
Cytek Biosciences's current Enterprise Value is $367.6 Mil.
Cytek Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a EV-to-OCF of -60.88 as of Aug. 11, 2026. According to the industry distribution chart, Cytek Biosciences ranks #48 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 5.6%.
Is Cytek Biosciences' EV-to-OCF too high?
Cytek Biosciences' current EV-to-OCF is -60.88. Based on the distribution chart, Cytek Biosciences ranks #48 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cytek Biosciences has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' EV-to-OCF compare to CERS and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #48 out of 853 companies for EV-to-OCF. This places Cytek Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.85, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current EV-to-OCF is -60.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.58, compared to a current price of $4.64 — trading 16.8% below its estimated fair value. The current EV-to-OCF is -60.88. Cytek Biosciences' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current EV-to-OCF is -60.88 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.64 is trading 16.8% below its estimated GF Value™ of $5.58.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
EV-to-OCF: -60.88
GF Value™: $5.58 vs. price of $4.64 (16.8% below fair value)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
70GF Score
Get the complete analysis for CTKB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
